. Author manuscript; available in PMC: 2019 Mar 6.

Published in final edited form as: J Clin Urol. 2018 Jul 23;12(2):122–128. doi: 10.1177/2051415818788240

Table 1.

Clinical characteristics between RPLND patients who received alvimopan versus those who did not.

Clinical characteristics	No Alvimopan (n=21)	Alvimopan (n=8)	p-value
Median age (years)	27	29.5	0.783
No. NSGCT (%)	20 (95.2)	6 (75.0)	0.176
No. post-chemotherapy (%)	16 (76.2)	7 (87.5)	0.647
Mean preoperative mass size (cm)	2.9	2.61	0.813
Body mass index (kg/m²)	32.1	26.8	0.105
Smoking history (%)	38	37.5	0.659
Mean Charlson comorbidity index	2.76	3	0.54
Mean transfusion units (pRBCs)	0.05	0	0.329
Mean EBL (mL)	371.1	493.7	0.477

RPLND: retroperitoneal lymph node dissection; NSGCT: non-seminomatous germ cell tumor; pRBCs: packed red blood cells; EBL: estimated blood loss.